Single-tablet HIV regimen (INSTI + booster + 2× NRTI)

Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide

Brand names: Genvoya

Adult dose

Dose: 1 tablet OD with food

Route: Oral

Frequency: OD

Clinical pearls

BHIVA-recommended option; TAF preferred over TDF for renal/bone protection
Monitor for cobicistat drug interactions at every prescription

Contraindications

Concurrent strong CYP3A4 inducers (rifampicin, carbamazepine, St John's wort)
Hypersensitivity

Side effects

GI upset
Headache
Insomnia
Renal (less than TDF)
Lipid changes (cobicistat)
Increased serum creatinine (cobicistat artefactual reduction in tubular secretion)

Interactions

Many — cobicistat is potent CYP3A4 inhibitor; statins, PPIs, antiarrhythmics, ergots, midazolam

Monitoring

VL/CD4
Renal
LFTs
Lipids
Bone health
Drug interactions

Reference: BNF; BHIVA HIV guidelines; EACS; SmPC; https://bnf.nice.org.uk/drugs/elvitegravir-with-cobicistat-emtricitabine-and-tenofovir-alafenamide/. Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Calculators

Drugs

Elvitegravir with cobicistat, emtricitabine and tenofovir disoproxil · Single-tablet HIV regimen (INSTI + booster + 2× NRTI)

Pathways